Henry Schein (NASDAQ:HSIC) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Henry Schein (NASDAQ:HSIC) from a hold rating to a buy rating in a report released on Saturday morning.

HSIC has been the topic of several other research reports. Wells Fargo & Company upped their price objective on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research report on Wednesday. JPMorgan Chase & Co. raised their price target on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday. Baird R W cut shares of Henry Schein from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 14th. Morgan Stanley upped their target price on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research note on Wednesday. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $75.00 price target (down previously from $80.00) on shares of Henry Schein in a research note on Friday, July 25th. Five equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $76.08.

Henry Schein Trading Up 2.6%

Shares of HSIC stock traded up $1.84 during trading hours on Friday, reaching $71.90. 1,452,270 shares of the stock were exchanged, compared to its average volume of 1,725,097. The firm has a market capitalization of $8.46 billion, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of 2.06 and a beta of 0.84. Henry Schein has a 12-month low of $60.56 and a 12-month high of $82.49. The company’s 50-day moving average price is $66.30 and its 200-day moving average price is $68.74. The company has a current ratio of 1.41, a quick ratio of 0.78 and a debt-to-equity ratio of 0.51.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The company had revenue of $3.34 billion for the quarter, compared to analyst estimates of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, equities analysts anticipate that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. CYBER HORNET ETFs LLC bought a new stake in Henry Schein during the second quarter valued at about $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein during the second quarter valued at about $27,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Henry Schein in the 2nd quarter valued at about $43,000. Steph & Co. bought a new stake in shares of Henry Schein in the 2nd quarter valued at about $44,000. Finally, CX Institutional grew its position in shares of Henry Schein by 107.3% in the 2nd quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after buying an additional 337 shares during the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.